LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

Search

Regeneron Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

588 -1.41

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

580.5

Max

596.65

Belangrijke statistieken

By Trading Economics

Inkomsten

-109M

809M

Verkoop

-761M

3B

K/W

Sectorgemiddelde

15.175

54.533

EPS

8.22

Dividendrendement

0.59

Winstmarge

26.701

Werknemers

15,158

EBITDA

-54M

1B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+37.88% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.59%

2.41%

Volgende Winsten

31 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-10B

64B

Vorige openingsprijs

589.41

Vorige sluitingsprijs

588

Nieuwssentiment

By Acuity

41%

59%

139 / 382 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Regeneron Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 mei 2025, 11:55 UTC

Acquisities, Fusies, Overnames

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million

29 apr 2025, 11:07 UTC

Winsten

Regeneron 1Q Profit Rises, Revenue Falls; FY25 CapEx Target Trimmed

4 feb 2025, 12:13 UTC

Winsten

Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD

19 mei 2025, 17:52 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- 2nd Update

19 mei 2025, 16:13 UTC

Acquisities, Fusies, Overnames

Regeneron Is Buying 23andMe. The Deal Is a Head Scratcher. -- Barrons.com

19 mei 2025, 14:42 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- 2nd Update

19 mei 2025, 13:33 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- Update

19 mei 2025, 11:10 UTC

Acquisities, Fusies, Overnames

Regeneron: To Ensure Compliance With 23andMe Consumer Privacy Policies, Applicable Laws on Customer Data >REGN

19 mei 2025, 11:10 UTC

Acquisities, Fusies, Overnames

Regeneron: 23andMe Transaction Expected to Close in 3Q >REGN

19 mei 2025, 11:09 UTC

Acquisities, Fusies, Overnames

Regeneron: To Continue All 23andMe Consumer Genome Services Uninterrupted >REGN

19 mei 2025, 11:08 UTC

Acquisities, Fusies, Overnames

Regeneron: Named Successful Bidder in Bankruptcy Auction for Substantially All Assets of 23andMe >REGN

29 apr 2025, 18:04 UTC

Marktinformatie
Winsten

Regeneron Sinks As Sales Of Key Eye Medication Tumble -- Market Talk

29 apr 2025, 14:39 UTC

Marktinformatie
Winsten

Regeneron's Eylea Setback Drags Stock as Investor Frustrations Mount -- Market Talk

29 apr 2025, 14:29 UTC

Winsten

Regeneron Stock Plummets After Earnings Miss -- Barrons.com

29 apr 2025, 13:11 UTC

Winsten

Regeneron Stock Plummets After Earnings Miss -- Barrons.com

29 apr 2025, 10:32 UTC

Winsten

Regeneron Pharma Cuts 2025 CapEx to $850M-$950M >REGN

29 apr 2025, 10:30 UTC

Winsten

Regeneron Pharma 1Q Rev $3.03B >REGN

29 apr 2025, 10:30 UTC

Winsten

Regeneron Pharma 1Q Net $808.7M >REGN

29 apr 2025, 10:30 UTC

Winsten

Regeneron Pharma 1Q EPS $7.27 >REGN

29 apr 2025, 10:30 UTC

Winsten

Regeneron Pharma 1Q Adj EPS $8.22 >REGN

22 apr 2025, 10:51 UTC

Top Nieuws

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs -- WSJ

28 feb 2025, 12:00 UTC

Top Nieuws

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4 feb 2025, 11:58 UTC

Winsten

Regeneron 4Q Rev Up on Strong Sales of EYLEA HD

4 feb 2025, 11:37 UTC

Winsten

Regeneron Pharma Sees 2025 Adjusted R&D $5B-$5.2B >REGN

4 feb 2025, 11:37 UTC

Winsten

Regeneron Pharma Sees 2025 Gross Margin on Net Product Sales 87%-88% >REGN

4 feb 2025, 11:36 UTC

Winsten

Regeneron Pharma Sees 2025 Capital Spending $850M-$975M >REGN

4 feb 2025, 11:35 UTC

Winsten

Regeneron Pharma Declares Initial Quarterly Dividend of 88c >REGN

4 feb 2025, 11:35 UTC

Winsten

Regeneron Pharma 4Q Adj EPS $12.07 >REGN

4 feb 2025, 11:34 UTC

Winsten

Regeneron Pharma 4Q U.S. Net Sales for Eylea HD, Eylea Rose 2% to $1.5B >REGN

4 feb 2025, 11:34 UTC

Winsten

Regeneron Pharma: 4Q Dupixent Global Net Sales Recorded by Sanofi Rose 15% to $3.7B >REGN

Peer Vergelijking

Prijswijziging

Regeneron Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

37.88% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 811.21 USD  37.88%

Hoogste 979 USD

Laagste 535 USD

Gebaseerd op 21 Wall Street-analisten die 12-maands prijsdoelen bieden voor Regeneron Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

21 ratings

18

Buy

2

Hold

1

Sell

Technische score

By Trading Central

542.44 / 599.76Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

139 / 382 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.